On March 28, 2024 BioSkryb Genomics, a company ushering in the next generation of single-cell technology, reported that it will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA (Press release, BioSkyrb, MAR 28, 2024, View Source [SID1234641601]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"ResolveOME’s unified workflow for single-cell analysis of genome and transcriptome enables phylogenetic reconstruction of somatic single cells with phenotypic annotation," said Dr. Dan Landau, New York Genome Center, who will present his team’s pioneering research using ResolveOME at BioSkryb’s Exhibitor Spotlight Theater on Tuesday, April 9. "Through this approach, we are now exploring the origin and dynamics of somatic evolution in both malignant and non-malignant human tissues."
BioSkryb will showcase the power of its newly launched automation-ready ResolveDNA and ResolveOME single-cell core kits, which provide a comprehensive and scalable end-to-end workflow for producing sequencing-ready libraries in under 8 hours. The new kits, which are now shipping to customers across the globe, enable single nucleotide variant (SNV), copy number variation (CNV), and structural variant (SV) calling in genomic DNA and allow scientists to perform multiomic characterization of individual cells through the integration of genomic and transcriptomic data from each cell.
"Tumor heterogeneity is a key challenge for researchers in the cancer research field. As tumors evolve, subclones emerge with mutations that convey adaptive phenotypes, including resistance to therapies," said Suresh Pisharody, CEO of BioSkryb. "Our next generation single-cell technology gives scientists the tools to better understand the way tumors evolve with a comprehensive, scalable, and streamlined workflow. We look forward to sharing how our new tools empower novel cancer research efforts in San Diego."
Posters and Presentations Featuring BioSkryb Technology
EXHIBITOR SPOTLIGHT THEATER PRESENTATION | Presenter: Dan Landau, MD, Ph.D., New York Genome Center | Single-cell mapping of lineage and phenotype in human somatic evolution
Tuesday, April 9, 12:30pm PT | Spotlight Theater C
Dr. Dan Landau from the New York Genome Center will discuss methods for deciphering the origin and dynamics of clonal evolution in somatic cells. This emerging research frontier has profound implications for understanding human aging and disease.
POSTER PRESENTATION | Presenter: Jon Zawistowski, Ph.D.| Inter- and intratumoral PIK3CA subclonal diversity in breast cancer contextualized by single-cell multiomics
Wednesday, April 10, 9:00am – 12:30pm PT
Poster Section 11
Abstract Number: 6929
BioSkryb will be at booth #704 at the meeting. To request a meeting or demo, please click here.